Induction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Murine Model of a Human Neuroendocrine Tumor

Induction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Murine Model of a Human Neuroendocrine Tumor

Peptide receptor radionuclide therapy (PRRT) is a relatively new mode of internally targeted radiotherapy currently in clinical trials. In PRRT, ionizing radioisotopes conjugated to somatostatin analogues are targeted to neuroendocrine tumors (NETs) via somatostatin receptors. Despite promising clin...

Full description

Bibliographic Details
Main Authors: Michael Bzorek, Michael Holmsgaard Kristensen, Andreas Kjaer, Andreas Klaus Pfeifer, Ulrich Knigge, Yin Wu, Rajendra Singh Garbyal, Palle Rasmussen, Rebecca Myschetzky
Format: Article
Language:English
Published: MDPI AG 2013-10-01
Series:Diagnostics
Subjects:
PRRT
177Lu-DOTATATE
CD86+
CD49b+
FasL+
dendritic cells
NK cells
Online Access:http://www.mdpi.com/2075-4418/3/4/344

Internet

http://www.mdpi.com/2075-4418/3/4/344

Similar Items